PMID: 15218422Jun 26, 2004Paper

Combined therapy with desferrioxamine and deferiprone: a new protocol for iron chelation in thalassemia

Journal of Pediatric Hematology/oncology
Emanuela D'AngeloVittorio Carnelli

Abstract

Deferiprone (DFO) at the standard daily dose of 75 mg/kg was given to 13 transfusion-dependent patients with thalassemia in whom conventional desferrioxamine (DFX) therapy had proven ineffective and caused adverse side effects. In six patients, serum ferritin and alanine aminotransferase levels decreased significantly and urinary iron excretion increased. In seven patients in whom DFO administration alone was ineffectual, DFX was added at a daily dose of 40 to 50 mg/kg given subcutaneously for 7 to 10 days following transfusion. All patients exhibited a significant decrease in serum ferritin levels and an increase in urinary iron excretion, with alanine aminotransferase levels decreased in four patients. The combined DFX and DFO therapy could represent an effective alternative to conventional DFX therapy not only in nonresponding patients with thalassemia but also, by lowering to less than 25% the DFX dosage, in patients who exhibit important DFX-related side effects.

References

Oct 1, 1990·British Journal of Haematology·A N BartlettG J Kontoghiorghes
Apr 6, 1995·The New England Journal of Medicine·N F OlivieriG Koren
Jun 1, 1996·British Journal of Haematology·A AraujoA V Hoffbrand
Jul 21, 1998·Annals of the New York Academy of Sciences·A CohenF Tricta
Nov 25, 1998·British Journal of Haematology·B WonkeA V Hoffbrand

❮ Previous
Next ❯

Citations

Jun 27, 1992·Lancet·V Macarol, S J Yawalkar
Feb 24, 2005·Current Opinion in Hematology·Melody J Cunningham, David G Nathan
Feb 11, 2014·Best Practice & Research. Clinical Haematology·David P Steensma, Norbert Gattermann
Dec 13, 2005·Annals of the New York Academy of Sciences·Antonis Kattamis
Dec 13, 2005·Annals of the New York Academy of Sciences·David G Nathan
Aug 18, 2010·Annals of the New York Academy of Sciences·Renzo GalanelloRobert W Grady
Aug 24, 2013·The Cochrane Database of Systematic Reviews·Sheila A FisherDavid J Roberts

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.